Drugs / Expanded Tregs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02145325 | Apr 2014 → Jun 2016 | end stage renal failure | Northwestern University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Expanded Tregs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02145325 ↗ |
| Modality | Cell therapy | “expanded Tregs cellular product” NCT02145325 ↗ |
| Route | Intravenous | “Expanded Tregs infusion intravenously” NCT02145325 ↗ |